Silence Therapeutics (SLN) Non-Current Assets (2018 - 2026)

Silence Therapeutics has disclosed Non-Current Assets across 9 years of filings, most recently posting $12.3 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $12.3 million, down 20.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.3 million (down 20.87% YoY), and the FY2025 annual result was $12.8 million, down 16.27% from the prior year.
• Non-Current Assets came in at $12.3 million for Q1 2026 at Silence Therapeutics, down from $12.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $16.7 million in Q2 2025 to a low of $12.3 million in Q1 2026.
• The 5-year median for Non-Current Assets is $14.2 million (2024), against an average of $14.3 million.
• Across the five-year window, Non-Current Assets grew 25.26% in 2023 and dropped 20.87% in 2026, its largest moves.
• Silence Therapeutics' Non-Current Assets stood at $12.7 million in 2022, then gained by 25.26% to $15.9 million in 2023, then slipped by 3.9% to $15.3 million in 2024, then decreased by 16.27% to $12.8 million in 2025, then dropped by 4.01% to $12.3 million in 2026.
• The last three Non-Current Assets figures came in at $12.3 million (Q1 2026), $12.8 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.